University spinout OxSight, has reported that in a recent UK-wide trial its smart glasses helped sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
A technology co-developed at the Universities of Oxford and Sao Paulo State University in Brazil will be commercialised by spinout OID (Oxford Impedance Diagnostics), offering the potential for ultrasensitive fast diagnostic tests for a range of diseases.
The fourth annual Oxford Technology Showcase was held on Wednesday 6th July at Oxford’s Saïd Business School. The event brought together experts and innovators from Oxford University, the Oxford University Hospital Trust and the Oxfordshire region. Over 300 investors, entrepreneurs, healthcare companies, researchers and clinicians attended.
In conjunction with Shakespeare’s Dead at the Bodleian’s Weston Library: TalkAbout Guides App available 1 July – 18 September 2016, free download for iOs and Android.
The latest technologies stemming from research at Oxford and Cambridge were presented Tuesday to investors at an event held at the Royal Society of Chemistry. With 17 spinouts already this calendar year, the two universities report that a similar joint event last year led directly to investment in several of the ventures that presented.
Isis Innovation will be renamed Oxford University Innovation, in order to enhance the already strong links between Isis Innovation and the University1. This will strengthen awareness of the company and its services within the wider University, and better portray the University’s ownership of the company.
Oxford spinout EvOx Therapeutics will harness the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.
Universal flu vaccine developed at Oxford already showing promise in Phase II clinical trials Large investment of £10m from Oxford Sciences Innovation Further programs include vaccines to boost cancer immunotherapies